At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
GNC-077drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics or Preliminary Efficacy and Antitumor Activity of GNC-077 Multi-specific Antibody Injection in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Other Solid Tumors
In Brief
A Phase 1 clinical trial evaluating GNC-077 for Non-small Cell Lung Cancer and Solid Tumor. Currently recruiting, targeting 20 participants across 1 site.
Detailed Summary
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with Locally advanced or metastatic non-small cell lung cancer and other solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer, Solid Tumor
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 1Recruiting
20252026
First PostedSep 2024
Enrollment StartOct 2024
TodayJul 2026
Primary CompletionOct 2026
First PostedSep 25, 2024
Enrollment StartOct 16, 2024
Primary CompletionOct 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 1.8 years agoPrimary completion in 3 months
Interventions
GNC-077drug
Administration by intravenous infusion for a cycle of 3 weeks.